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 SNOT 22 in a Control Population 
 
The CRES Group 
Aim: 
To assess SNOT-22 and its subscales in a non-rhinosinusitis UK-wide population. 
 
Methodology/Principle 
This analysis uses data from the ‘Chronic Rhinosinusitis Epidemiology Study’ (CRES) which 
recruited from 30 centres across the UK, and the Socioeconomic Cost of ChrOnic 
Rhinosinusitis study’ (SocCoR); 250 volunteers without CRS were recruited as part of 
these studies. Study-specific questionnaires including demographics, socioeconomic 
factors and past medical history as well as SNOT-22 and SF-36 were distributed. The 
control (non-CRS) population had no self-reported nasal problems in the past, no chronic 
conditions undergoing active treatment and no hospital admissions in the preceding 12 
months. 
 
Results:  
The mean SNOT-22 total score overall was 12.0. The mean was 10.2 for males with a 
median of 6.5, and a mean of 13.2 for females with a median of 9.  Females scored 
significantly more highly than males on the sleep/fatigue and facial domains. 
 
Conclusions 
Our data demonstrate differences in SNOT-22 amongst males and females. These data 
can be used in future studies for comparison with different disease populations with 
rhinosinusitis. 
 
 
 
 
 
 
Introduction 
Chronic rhinosinusitis (CRS) affects a significant proportion of the population; a recent 
European study found a prevalence of 11% (Hastan, Fokkens et al. 2011). Patient reported 
outcome measures (PROMs) are a means of collecting information on the effectiveness 
of care delivered to patients, as perceived by the patients themselves, and are 
increasingly important in clinical practice and in research (Timmins 2008, HaSCI 2014) 
(Greenhalgh, Long et al. 2005) on a background of increasing costs of healthcare across 
the world. The most widely accepted and best validated patient self-report symptom 
evaluation tool for use in CRS is the SNOT-22, whose 22 items incorporate both nasal and 
non-nasal symptoms(Hopkins, Gillett et al. 2009)(Rudmik, Hopkins et al. 2015). Within 
SNOT-22, self-reported symptom severity is graded from 0-5, with 5 being a severe 
problem.  It is a modification of the 31-question Rhinosinusitis Outcome Measure (RSOM-
31)(Piccirillo, Edwards et al. 1995). Factor analysis identifies four principal SNOT domains 
– nasal, facial, sleep and mood (Browne, Hopkins et al. 2007) (Lange, Thilsing et al. 2011, 
Lange, Holst et al. 2013, DeConde, Mace et al. 2014). Factor analysis for SNOT-22 was 
validated in a Danish population of 40 patients (Lange, Thilsing et al. 2011).The four 
subscales are:- rhinological symptoms (questions 1-5, 7and 8), ear and facial symptoms 
(questions 9-12), sleep function (questions 13-15) and psychological issues (questions 17-
22). The questions regarding cough and waking up tired were not included in these 
subscales. There are limited SNOT-22 data for a non-CRS population, particularly from 
within the UK (Farhood, Schlosser et al. 2015). 
  
The overarching aim of the Chronic Rhinosinusitis Epidemiology Study (CRES) was to aid 
better understanding of medical and non-medical factors contributing to development 
or worsening of CRS. The aim of the Socioeconomic Cost of ChrOnic Rhinosinusitis study 
(SocCoR) was to identify the socio-economic costs of CRS to improve the understanding 
of the impact of CRS disease to the patient and the NHS. The purpose of this analysis 
was to yield large dataset of SNOT-22 information for a control population in the UK. 
 
 Materials and Methods 
 
CRES was conducted as a cross-sectional cohort study and recruited from a total of 30 
sites from around the UK (including the devolved nations of Wales and Scotland), 
between 2007 and 2013. Controls included family and friends of those attending ENT 
outpatient clinics and hospital staff, inclusion criteria required that they had no diagnosis 
of persistent nose or sinus problems and had not been admitted to hospital in the 
previous 12 months. Questionnaires were returned by participants using a Freepost 
envelope and scanned to a secure database using Formic. Two members of the research 
team checked the accuracy of electronic scanning of returned questionnaires. The SocCoR 
study recruited participants meeting the same criteria, but only from East Anglia 
 
The CRES was approved by the Oxford C Research Ethics Committee, sponsored by the 
University of East Anglia (UEA) and funded by the Anthony Long and Bernice Bibby Trusts. 
The study specific questionnaire was anonymous and therefore no consent was taken but 
implied through participation. Participant information leaflets were provided. SocCoR 
was approved by the North Scotland REC1 Research Ethics Committee. 
 
 Results  
A total of 251 non-CRS controls completed the SNOT-22 questionnaire. 
Participation rate for the study overall was 66%, data were not specifically collected 
regarding controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: SNOT-22 and its subscales 
 
  Age 
(range) 
SNOT-22 Nasal Facial Sleep 
fatigue 
Emotional 
 n  mean (sd) Median 
(IQR) 
mean (sd) mean (sd) mean (sd) mean (sd) 
Total 251 47.5  
(19-80) 
12.0 (13.6) 8 (2-17) 2.5 (4.0) 1.1 (2.5) 2.9 (3.6) 3.5 (5.3) 
Females 143 46.8 
(14.4) 
19-80 
13.2 (15.0) 9 (2-18) 2.3 (3.6) 1.4 (2.9) 3.4 (3.9) 3.8 (6.0) 
Males 96 48.8 
(15.8) 
22-82 
10.2 (11.1) 6.5 (2-14.5) 2.8 (4.4) 0.7 (1.4) 2.2 (2.7) 3.0 (4.1) 
Differences 
(p values) 
  0.0921 0.2973 0.3632 0.0061 0.0051 0.1931 
 
1t-test (unequal variances) ;  2 t-test (equal variances) ; 3 Mann-Whitney test 
 
 
Boxplot to show SNOT-22 for males and females
 
 
 
Females                                      Males 
  
 
 
Females tended to score more highly than males overall. They also had a wider range of 
scores. Females scored more highly on each of the domains; this was statistically 
significant within the sleep fatigue and facial domains.  
Participants were asked about the frequency at which they suffer from upper 
respiratory tract infections; no differences were found in the numbers of upper 
respiratory tract infections between males and females. 
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Table to characterize outliers 
Total SNOT-22 Nasal Domain 
(% of total 
domain score) 
Facial Domain Sleep Domain Emotional 
Domain 
Females  
85 
21 (60) 17 (85) 15 (100) 26 (87) 
63 13 (37) 15 (75) 9 (60) 21 (70) 
55 14 (51) 6 (30) 10 (67) 18 (60) 
52 5 (14) 2 (10) 15 (100) 26 (87) 
45 18 (51) 10 (50) 4 (27) 13 (43) 
43 8 (23) 2 (10) 9 (60) 21 (70) 
Males 
62 
19 (54) 9 (45) 10(75) 18 (60) 
38 20 (57) 0  3 (20) 11 (37) 
34 14 (51) 0 6 (40) 11 (37) 
32 1 (3) 0 10 (75) 18 (60) 
 
The table of outliers shows that outlying females tended to score highest amongst sleep 
and emotional domains. Outlying males scored highly across all domains other than 
facial. 
 
 
Discussion  
Our data describe a large population of non-CRS volunteers from across the UK. We found 
a mean SNOT-22 score of 10.2 for males with a median of 6.5, and a mean of 13.2 for 
females with a median of 9.  The standard deviation was higher amongst females. Our 
control results were not normally distributed; this is to be expected since there should be 
a large number of individuals who score very low (floor effect). Previous studies of a 
healthy control population have found a median of 7-9 (Gillett, Hopkins et al. 2009, 
Gregório, Andrade et al. 2015).  The population (n=116) recruited by Gillett et al included 
a higher proportion of males and also those recruited through a tennis club who may have 
been healthier than the general population.  A study using a random sample of the Danish 
population (n=271 for those without CRS) similarly found a median SNOT-22 value of 7 
(IQR2-15), (Lange, Holst et al. 2013, Lange, Thilsing et al. 2015); they do not differentiate 
by gender. In a study of 539 healthy volunteers in Sao Paulo, Gregorio et al also found 
SNOT-22 scores were distributed significantly differently between men and women. Men 
presented significantly lower normal values than women (men: mean = 8.58 and median 
= 7 versus women: mean = 10.94 and median = 9;p = 0.005). A median score of 7-10 for 
males and 9-13 for females therefore appears to be reproducible benchmark for ‘normal’ 
SNOT-22.       A recent systematic review of SNOT-22 scores in a non-CRS population found 
that scores varied significantly according to the nature of the group studied (Farhood, 
Schlosser et al. 2015). The review also found differences between those with and without 
asthma and amongst smokers. Similar results were found in the CRES study between all 
subgroups of CRS patients, and will be reported elsewhere. The importance of using non-
CRS SNOT scores from a comparable population is therefore key, and our data provide 
this for a very diverse UK population. The average SNOT-22 score identified should not be 
used as an ‘absolute’ normal score to assign care for CRS or as a diagnostic threshold, but 
is a useful figure to consider when assessing SNOT-22 in the context of CRS in both clinic 
and research. 
 
Conclusion 
Our data provide reference data for scores across SNOT-22 in a non-CRS population across 
a wide cross section of the UK population and they demonstrate the differences in 
reporting in males and females. These data can be used in future studies for comparison 
with different disease populations with rhinosinusitis. 
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